Bayer’s Dual Gamble: A Supreme Court Pivot and a Cash-Strapped Reboot

Bayer shares tumble as investors weigh a potential Supreme Court win against mounting debt, negative cash flow, and €5B in legal payouts.

In a week where Bayer’s stock has shed nearly a tenth of its value, the German conglomerate finds itself caught between the promise of a landmark legal victory and the grinding realities of a balance sheet under siege. The shares, trading around €36.45, have been whipsawed by a mix of cautious optimism from the Supreme Court and deep-seated investor unease over debt and cash flow.

The catalyst for the recent jitters was Monday’s oral arguments in the Durnell case, a test of whether federal labeling laws preempt state-level claims over glyphosate. While Bayer’s legal team left Washington feeling upbeat, the market has taken a more skeptical view. Analysts at UBS, however, see reason for hope. Drawing on insights from the US law firm Morgan & Morgan, they peg the probability of a Bayer-friendly ruling at roughly 70%. Analyst Matthew Weston maintains a “Buy” rating with a €52 price target, arguing that a win at the Supreme Court would set a decisive precedent for handling the remaining US litigation. A final decision is expected by the end of June.

Yet the courtroom drama is only half the story. On Wednesday, Bayer paid out a token dividend of just €0.11 per share, a stark reminder of the financial constraints gripping the company. CFO Wolfgang Nickl has framed the austerity as essential for debt reduction, but the numbers paint a grim picture. Net financial debt stands at nearly €30 billion and is expected to edge higher this year, while free cash flow remains stuck in negative territory. The company has earmarked around €5 billion for legal settlements in 6 alone, a sum that one prominent shareholder activist described as money “flowing into the past, not the future.”

The tension between operational progress and financial fragility was on full display at the recent annual general meeting. CEO Bill Anderson doubled down on his “Dynamic Shared Ownership” restructuring plan, which aims to slash hierarchies and speed up decision-making. Early signs of traction are visible in the pharma division, where drugs like Nubeqa and Kerendia are delivering strong growth. Management sees particular upside for Kerendia following expanded regulatory approvals.

But investors remain unconvinced. The shareholder base is fractured over strategy. Deka is pushing for an open-ended review of the corporate structure, including potential spin-offs. Union Investment backs the current path, warning against too many simultaneous initiatives. The DWS, meanwhile, is calling for faster execution. The core problem, as articulated by Marc Tüngler of the DSW shareholder association, is that the company’s cash is being consumed by legacy liabilities rather than invested in future growth.

The next major test arrives on May 12, when Bayer reports first-quarter results. The market will be watching closely to see whether the leaner structures at Crop Science and Pharmaceuticals are beginning to translate into measurable improvements in profitability. For the full year, management is targeting revenue of up to €47 billion and an operating result of no more than €10.1 billion.

For now, Bayer’s trajectory hinges on two very different timelines: a Supreme Court ruling that could reshape its legal landscape, and a quarterly earnings report that will test whether the turnaround is real. Both are due within weeks of each other, and both carry enormous weight for a company trying to rewrite its narrative.